Regulation of MCP-1 production in brain by stress and noradrenaline- modulating drugs

Journal of Neurochemistry

Volumn 113, Issue 2, 2010, Pages 543-551

  Madrigal, Jose L M ^a   Garcia Bueno, Borja ^a   Hinojosa, Ara E ^a   Polak, Paul ^b   Feinstein, Douglas L ^b   Leza, Juan C ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

CCL2; Depression; Desipramine; MCP 1; Noradrenaline; Stress

Indexed keywords

CORTICOSTERONE; DESIPRAMINE; GLUCOCORTICOID; METYRAPONE; MONOCYTE CHEMOTACTIC PROTEIN 1; NORADRENALIN; PROPRANOLOL; THREO 3,4 DIHYDROXYPHENYLSERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASTROCYTE; BRAIN CORTEX; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STRESS; TISSUE LEVEL;

ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ALDEHYDE-LYASES; ANIMALS; ASTROCYTES; BENSERAZIDE; BRAIN; CHEMOKINE CCL2; CORTICOSTERONE; DESIPRAMINE; DRUG ADMINISTRATION ROUTES; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION; MALE; METYRAPONE; MICE; MICE, INBRED C57BL; NOREPINEPHRINE; PROPRANOLOL; RATS; RATS, WISTAR; RESTRAINT, PHYSICAL; RNA, MESSENGER; STRESS, PHYSIOLOGICAL;

MUS; RATTUS;

EID: 77949721179     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2010.06623.x     Document Type: Article

References (46)

1. Babcock A. A., Kuziel W. A., Rivest S. Owens T. (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J. Neurosci. 23, 7922 7930.
2. Ballantyne C. M. Nambi V. (2005) Markers of inflammation and their clinical significance. Atheroscler. Suppl. 6, 21 29.
3. Belmadani A., Tran P. B., Ren D. Miller R. J. (2006) Chemokines regulate the migration of neural progenitors to sites of neuroinflammation. J. Neurosci. 26, 3182 3191.
4. Berton O. Nestler E. J. (2006) New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 7, 137 151.
5. Bondareff W., Mountjoy C. Q. Roth M. (1981) Selective loss of neurones of origin of adrenergic projection to cerebral cortex (nucleus locus coeruleus) in senile dementia. Lancet 1, 783 784.
6. Bremner J. D. (2007) Neuroimaging in posttraumatic stress disorder and other stress-related disorders. Neuroimaging Clin. N. Am. 17, 523 538, ix.
7. Bremner J. D., Krystal J. H., Southwick S. M. Charney D. S. (1996a) Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 23, 28 38.
8. Bremner J. D., Krystal J. H., Southwick S. M. Charney D. S. (1996b) Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 23, 39 51.
9. Bruno V., Copani A., Besong G., Scoto G. Nicoletti F. (2000) Neuroprotective activity of chemokines against N-methyl-D-aspartate or beta-amyloid-induced toxicity in culture. Eur. J. Pharmacol. 399, 117 121.
10. Cardona A. E., Li M., Liu L., Savarin C. Ransohoff R. M. (2008) Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation. J. Leukoc. Biol. 84, 587 594.
11. Carroll B. J., Curtis G. C. Mendels J. (1976) Cerebrospinal fluid and plasma free cortisol concentrations in depression. Psychol. Med. 6, 235 244.
12. Charo I. F. Taubman M. B. (2004) Chemokines in the pathogenesis of vascular disease. Circ. Res. 95, 858 866.
13. Dansereau M. A., Gosselin R. D., Pohl M. et al. (2008) Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J. Neurochem. 106, 757 769.
14. Deshmane S. L., Kremlev S., Amini S. Sawaya B. E. (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res. 29, 313 326.
15. Eugenin E. A., D'Aversa T. G., Lopez L., Calderon T. M. Berman J. W. (2003) MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. J. Neurochem. 85, 1299 1311.
16. Fornai F., di Poggio A. B., Pellegrini A., Ruggieri S. Paparelli A. (2007) Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr. Med. Chem. 14, 2330 2334.
17. Galea E., Heneka M. T., Dello R. C. Feinstein D. L. (2003) Intrinsic regulation of brain inflammatory responses. Cell. Mol. Neurobiol. 23, 625 635.
18. Glabinski A. R., Balasingam V., Tani M., Kunkel S. L., Strieter R. M., Yong V. W. Ransohoff R. M. (1996) Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. J. Immunol. 156, 4363 4368.
19. Glavin G. B. (1985) Stress and brain noradrenaline: a review. Neurosci. Biobehav. Rev. 9, 233 243.
20. Harkness K. A., Sussman J. D., vies-Jones G. A., Greenwood J. Woodroofe M. N. (2003) Cytokine regulation of MCP-1 expression in brain and retinal microvascular endothelial cells. J. Neuroimmunol. 142, 1 9.
21. Heneka M. T., Ramanathan M., Jacobs A. H. et al. (2006) Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343 1354.
22. Inazu M., Takeda H. Matsumiya T. (2003) Functional expression of the norepinephrine transporter in cultured rat astrocytes. J. Neurochem. 84, 136 144.
23. Jung H., Toth P. T., White F. A. Miller R. J. (2008) Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J. Neurochem. 104, 254 263.
24. Kalinin S., Polak P. E., Madrigal J. L., Gavrilyuk V., Sharp A., Chauhan N., Marien M., Colpaert F. Feinstein D. L. (2006) Beta-amyloid-dependent expression of NOS2 in neurons: prevention by an alpha2-adrenergic antagonist. Antioxid. Redox Signal. 8, 873 883.
25. Kalinin S., Gavrilyuk V., Polak P. E., Vasser R., Zhao J., Heneka M. T. Feinstein D. L. (2007) Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol. Aging 28, 1206 1214.
26. Kawahara R. S., Deng Z. W. Deuel T. F. (1991) Glucocorticoids inhibit the transcriptional induction of JE, a platelet-derived growth factor-inducible gene. J. Biol. Chem. 266, 13261 13266.
27. Kikuchi K., Nishino K. Ohyu H. (2000) Increasing CNS norepinephrine levels by the precursor L-DOPS facilitates beam-walking recovery after sensorimotor cortex ablation in rats. Brain Res. 860, 130 135.
28. Kiyota T., Yamamoto M., Xiong H., Lambert M. P., Klein W. L., Gendelman H. E., Ransohoff R. M. Ikezu T. (2009) CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS ONE 4, e6197.
29. Kvetnansky R., Fukuhara K., Pacak K., Cizza G., Goldstein D. S. Kopin I. J. (1993) Endogenous glucocorticoids restrain catecholamine synthesis and release at rest and during immobilization stress in rats. Endocrinology 133, 1411 1419.
30. Leonard B. E. (1997) The role of noradrenaline in depression: a review. J. Psychopharmacol. 11, S39 S47.
31. Little A. R., Sriram K. O'Callaghan J. P. (2006) Corticosterone regulates expression of CCL2 in the intact and chemically injured hippocampus. Neurosci. Lett. 399, 162 166.
32. Madrigal J. L., Dello R. C., Gavrilyuk V. Feinstein D. L. (2006) Effects of noradrenaline on neuronal NOS2 expression and viability. Antioxid. Redox Signal. 8, 885 892.
33. Madrigal J. L., Leza J. C., Polak P., Kalinin S. Feinstein D. L. (2009) Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J. Neurosci. 29, 263 267.
34. Marinelli M., Le M. M. Piazza P. V. (1996) Acute pharmacological blockade of corticosterone secretion reverses food restriction-induced sensitization of the locomotor response to cocaine. Brain Res. 724, 251 255.
35. Melik-Parsadaniantz S. Rostene W. (2008) Chemokines and neuromodulation. J. Neuroimmunol. 198, 62 68.
36. Mizobe K., Kishihara K., Ezz-Din El-Naggar R., Madkour G. A., Kubo C. Nomoto K. (1997) Restraint stress-induced elevation of endogenous glucocorticoid suppresses migration of granulocytes and macrophages to an inflammatory locus. J. Neuroimmunol. 73, 81 89.
37. Morilak D. A., Barrera G., Echevarria D. J., Garcia A. S., Hernandez A., Ma S. Petre C. O. (2005) Role of brain norepinephrine in the behavioral response to stress. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 1214 1224.
38. Quattrone A., Annunziato L., Aguglia U. Preziosi P. (1981) Carbamazepine, phenytoin and phenobarbital do not influence brain catecholamine uptake, in vivo, in male rats. Arch. Int. Pharmacodyn. Ther. 252, 180 185.
39. Rauggi R., Cassanelli A., Raone A., Tagliamonte A. Gambarana C. (2005) Study of mirtazapine antidepressant effects in rats. Int. J. Neuropsychopharmacol. 8, 369 379.
40. Sapolsky R. M., Romero L. M. Munck A. U. (2000) How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr. Rev. 21, 55 89.
41. Sato E., Irie T. Katsube J. (1987) Effect of L-threo-3,4- dihydroxyphenylserine (L-DOPS), an immediate precursor of norepinephrine, on the cerebral blood flow in rats. Jpn. J. Pharmacol. 43, 91 93.
42. Schleimer R. P. (1993) An overview of glucocorticoid anti-inflammatory actions. Eur. J. Clin. Pharmacol. 45 (Suppl 1 S3 S7.
43. Thompson W. L., Karpus W. J. Van Eldik L. J. (2008) MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J. Neuroinflammation 5, 35.
44. Van D. V., Tekstra J., Beelen R. H., Tensen C. P., Van D. V. De Groot C. J. (1999) Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am. J. Pathol. 154, 45 51.
45. Wenk G. L. (2006) Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J. Clin. Psychiatry 67 (Suppl 3 3 7.
46. Zhou Y., Ling E. A. Dheen S. T. (2007) Dexamethasone suppresses monocyte chemoattractant protein-1 production via mitogen activated protein kinase phosphatase-1 dependent inhibition of Jun N-terminal kinase and p38 mitogen-activated protein kinase in activated rat microglia. J. Neurochem. 102, 667 678.